SUBSCRIBE
SUBSCRIBE

Clinical research

Policy
Biopharma Update on the Novel Coronavirus: May 22
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 22, 2020.
May 22, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
New researches on probable cure for HIV approachin
Drug Development
ImmunityBio’s Promising Preclinical HIV Drug is Moving into Phase I Trials
To learn more about ImmunityBio’s HIV drug candidate, BioSpace spoke to Dr. Whitney and Jeffrey Safrit, PhD, director of Cell-Mediated Therapies in Virology at NantKwest.
May 21, 2020
 · 
9 min read
 · 
Chelsea Weidman Burke
Drug Development
High Dose of Gilead and Galapagos’ JAK-Inhibitor Filgotinib Hits the Mark in UC Study
A high dose of filgotinib, the JAK1 inhibitor under long-term development by Gilead Sciences and Galapagos NV, proved effective in a Phase IIb/III study as a treatment for patients with moderately to severely active ulcerative colitis.
May 21, 2020
 · 
2 min read
 · 
Alex Keown
Policy
Biopharma Update on the Novel Coronavirus: May 21
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 21, 2020.
May 21, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Drug Development
Atea Pharma to Launch Phase II Trial Against COVID-19 After Raising $215 Million Series D
In addition to the COVID-19 development, the company plans to use the proceeds toward its pipeline of highly selective direct acting antivirals that target other severe RNA virus infections.
May 20, 2020
 · 
3 min read
 · 
Mark Terry
Policy
Biopharma Update on the Novel Coronavirus: May 20
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 20, 2020.
May 20, 2020
 · 
6 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: May 19
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 19, 2020.
May 19, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Drug Development
Moderna’s Preliminary Phase I COVID-19 Vaccine Data Shows Safety and Efficacy
Moderna released positive interim Phase I data from its clinical trial of mRNA-1273, its mRNA vaccine against SARS-CoV-2.
May 18, 2020
 · 
4 min read
 · 
Mark Terry
Policy
Biopharma Update on the Novel Coronavirus: May 18
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 18, 2020.
May 18, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Bio NC
Clinical Catch-Up: May 11-15
Clinical trial updates not related to COVID-19 are on the upswing, partly because some companies are announcing trial information ahead of the upcoming American Society of Clinical Oncology virtual meeting being held at the end of the month. Here’s a look.
May 15, 2020
 · 
12 min read
 · 
Mark Terry
Load More
PRESS RELEASES
Press Releases
Idorsia to present long-term lucerastat data and kidney biopsy results at WORLDSymposium
January 30, 2026
 · 
9 min read
Press Releases
MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients
January 30, 2026
 · 
7 min read
Press Releases
Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia
January 30, 2026
 · 
6 min read
Press Releases
Regentis Expanding Pivotal Phase III GelrinC Clinical Site Network: Adding Several Leading Orthopedic Centers Across the U.S.
January 29, 2026
 · 
7 min read
Press Releases
SK bioscience Initiates International Phase 1/2 Clinical Trial of Universal Vaccine Candidate Targeting Sarbecovirus Family
January 29, 2026
 · 
5 min read
Press Releases
MicuRx Announces FDA Clearance of IND Application to Proceed to Phase 2a Trial of MRX-5 in Patients with Mycobacterium abscessus Pulmonary Disease
January 29, 2026
 · 
2 min read
Press Releases
Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor
January 29, 2026
 · 
4 min read
Press Releases
Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan
January 29, 2026
 · 
7 min read
Press Releases
Innovative Molecules Announces Completion of Phase 1 Program and Advancement to Phase 2 for Oral Adibelivir
January 29, 2026
 · 
1 min read
Press Releases
Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
January 29, 2026
 · 
6 min read
Press Releases
Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne
January 29, 2026
 · 
3 min read
Press Releases
OMEICOS Therapeutics Announces Positive Phase 2 Study Outcome Demonstrating OMT-28’s Potential in Primary Mitochondrial Diseases (PMD)
January 29, 2026
 · 
5 min read
Press Releases
Study Results of Novel TYK2 Inhibitor Soficitinib in Patients with AD Published by JAMA Dermatology
January 29, 2026
 · 
4 min read
Press Releases
Aicuris Announces Pritelivir Phase 3 HSV Data to Be Presented as Late-Breaking Oral Presentation at Tandem
January 29, 2026
 · 
2 min read
Press Releases
ENA Respiratory Announces Dosing of First Participants in Phase II Study of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections
January 29, 2026
 · 
4 min read
Press Releases
OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab
January 29, 2026
 · 
8 min read
Press Releases
Tenpoint Therapeutics Ltd. Announces FDA Approval of YUVEZZI™, the First and Only Combination Eye Drop Approved to Treat Presbyopia
January 29, 2026
 · 
8 min read
Press Releases
QureBio Ltd. to Present at ASCO 2026 its Q-1802 Phase II Clinical Results
January 29, 2026
 · 
3 min read
Press Releases
Natera Announces Completion of Enrollment in Randomized ACES-EMB Trial in Heart Transplantation
January 29, 2026
 · 
3 min read
Press Releases
nChroma Bio Announces First Patient Dosed in Phase 1/2 Clinical Trial of Epigenetic Silencer CRMA-1001 for Chronic Hepatitis B
January 29, 2026
 · 
2 min read
Load More